Many New Oncology Drugs In 2012, With Prices That Test The Limits
Ten thousand dollars per month for new oncology drugs has become just about standard, and the trend is not likely to go away soon. Drug makers in 2012 found pricing in oncology to be inelastic and continue to test the boundaries within which payors – and society – will play.
You may also be interested in...
Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica
With a monthly cost of $10,900/month for the ultra-rare disease mantle cell lymphoma, Pharmacyclics and Janssen are being proactive about patient aid with a 30-day offer while reimbursement is worked out, as well as other support offerings that have become part of the new reality for high-priced oncologics.
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).
GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf
At a time when $10,000-per-month pricing is the norm in oncology, GSK has priced its just-approved BRAF inhibitor Tafinlar at $7,600, on the lower end by today’s standards. Company says it is planning to file the combination of Tafinlar with Mekinist – also just approved by FDA – in a matter of weeks in the U.S.